Alnylam Pharmaceuticals Inc (0HD2.L)

Name: Alnylam Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$1.1B

Net Income

$186M

Operating Margin

12.0%

Free Cash Flow

$465M

Debt / Assets

84.1%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Alnylam Pharmaceuticals Inc (0HD2.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	1,097,033,000	1,249,026,000	773,689,000	594,189,000
Cost of Revenue	267,723,000	197,231,000	142,953,000	71,041,000
Gross Profit	829,310,000	1,051,795,000	630,736,000	523,148,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	325,374,000	322,076,000	323,314,000	239,949,000
Operating Expenses	697,592,000	683,813,000	646,935,000	505,071,000
Operating Income	131,718,000	367,982,000	-16,199,000	18,077,000
Interest Expense	129,336,999	44,398,000	40,246,000	38,646,000
Income Before Tax	161,137,000	238,969,000	-35,358,000	-41,596,000
Income Tax Expense	-25,282,000	-12,115,000	30,919,000	15,883,000
Net Income	186,419,000	251,084,000	-66,277,000	-57,479,000
Per Share
EPS	1.41	1.91	-0.51	-0.44
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Alnylam Pharmaceuticals Inc (0HD2.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	3,713,937,000	2,248,243,000	1,828,292,000	1,037,417,999
Cost of Revenue	677,166,000	323,370,000	310,406,000	168,817,000
Gross Profit	3,036,771,000	1,924,873,000	1,517,886,000	868,600,999
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,210,713,000	975,526,000	795,646,000	770,658,000
Operating Expenses	2,535,193,000	2,101,758,000	1,800,061,000	1,653,673,000
Operating Income	501,578,000	-176,885,000	-282,175,000	-785,072,000
Interest Expense	252,627,000	141,858,000	121,221,000	155,968,000
Income Before Tax	323,152,000	-377,375,000	-433,517,000	-1,126,993,000
Income Tax Expense	9,405,000	-99,218,000	6,725,000	4,163,000
Net Income	313,747,000	-278,157,000	-440,242,000	-1,131,156,000
Per Share
EPS	2.39	-2.18	-3.52	-9.30
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Alnylam Pharmaceuticals Inc (0HD2.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	1,657,250,000	966,428,000	812,688,000	866,394,000
Short Term Investments	1,251,234,000	1,728,076,000	1,626,694,000	1,326,012,000
Net Receivables	777,567,000	405,308,000	327,787,000	237,963,000
Inventory	82,719,000	78,509,000	89,146,000	128,961,999
Total Current Assets	4,050,662,000	3,295,285,000	2,982,697,000	2,692,247,000
Property Plant Equipment	708,063,000	693,932,000	725,789,000	738,630,000
Goodwill and Intangibles	0	0	697,784,000	0
Total Assets	4,966,331,000	4,239,983,000	3,829,880,000	3,546,359,000
Liabilities
Account Payables	115,721,000	88,415,000	55,519,000	98,094,000
Short Term Debt	45,518,000	154,904,000	96,501,000	82,256,000
Total Current Liabilities	1,466,349,000	1,186,272,000	967,786,000	767,915,000
Long Term Debt	1,232,871,000	2,588,515,000	2,586,125,000	2,268,957,000
Total Liabilities	4,177,155,000	4,172,895,000	4,050,524,000	3,704,582,000
Shareholders Equity
Retained Earnings	-6,702,524,000	-7,287,748,000	-7,009,591,000	-6,569,349,000
Total Shareholders Equity	789,176,000	67,088,000	-220,644,000	-158,223,000

Balance sheet annual history for Alnylam Pharmaceuticals Inc (0HD2.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	1,657,250,000	966,428,000	812,688,000	866,394,000
Short Term Investments	1,251,234,000	1,728,076,000	1,626,694,000	1,326,012,000
Net Receivables	777,567,000	405,308,000	327,787,000	237,963,000
Inventory	82,719,000	78,509,000	89,146,000	128,961,999
Total Current Assets	4,050,662,000	3,295,285,000	2,982,697,000	2,692,247,000
Property Plant Equipment	708,063,000	693,932,000	725,789,000	738,630,000
Goodwill and Intangibles	0	0	697,784,000	0
Total Assets	4,966,331,000	4,239,983,000	3,829,880,000	3,546,359,000
Liabilities
Account Payables	115,721,000	88,415,000	55,519,000	98,094,000
Short Term Debt	45,518,000	154,904,000	96,501,000	82,256,000
Total Current Liabilities	1,466,349,000	1,186,272,000	967,786,000	767,915,000
Long Term Debt	1,232,871,000	2,588,515,000	2,586,125,000	2,268,957,000
Total Liabilities	4,177,155,000	4,172,895,000	4,050,524,000	3,704,582,000
Shareholders Equity
Retained Earnings	-6,702,524,000	-7,287,748,000	-7,009,591,000	-6,569,349,000
Total Shareholders Equity	789,176,000	67,088,000	-220,644,000	-158,223,000

Cash flow quarterly history for Alnylam Pharmaceuticals Inc (0HD2.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	313,747,000	-278,157,000	-440,242,000	-1,131,156,000
Depreciation & Amortization	55,658,000	56,670,000	97,031,000	44,468,000
Stock Based Compensation	348,235,000	272,084,000	221,680,000	230,649,000
Change in Working Capital	-444,782,000	-214,084,000	10,759,000	-35,553,000
Operating Cash Flow	524,080,000	-8,312,000	104,156,000	-541,274,000
Investing Activities
Capital Expenditure	-58,697,000	-34,277,000	-62,211,000	-72,059,000
Investments	-58,697,000	-34,277,000	-62,211,000	-72,059,000
Investing Cash Flow	436,329,000	-116,840,000	-336,350,000	169,354,000
Financing Activities
Debt Repayment	-546,946,000	0	0	-135,393,000
Common Stock Issued/Repurchased	250,028,000	302,951,000	147,464,000	259,360,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-305,190,000	294,159,000	172,131,000	425,753,000
Summary
Free Cash Flow	465,383,000	-42,589,000	41,945,000	-613,333,000
Net Change in Cash	690,155,000	153,768,000	-53,672,000	44,241,000

Cash flow annual history for Alnylam Pharmaceuticals Inc (0HD2.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	313,747,000	-278,157,000	-440,242,000	-1,131,156,000
Depreciation & Amortization	55,658,000	56,670,000	97,031,000	44,468,000
Stock Based Compensation	348,235,000	272,084,000	221,680,000	230,649,000
Change in Working Capital	-444,782,000	-214,084,000	10,759,000	-35,553,000
Operating Cash Flow	524,080,000	-8,312,000	104,156,000	-541,274,000
Investing Activities
Capital Expenditure	-58,697,000	-34,277,000	-62,211,000	-72,059,000
Investments	-58,697,000	-34,277,000	-62,211,000	-72,059,000
Investing Cash Flow	436,329,000	-116,840,000	-336,350,000	169,354,000
Financing Activities
Debt Repayment	-546,946,000	0	0	-135,393,000
Common Stock Issued/Repurchased	250,028,000	302,951,000	147,464,000	259,360,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-305,190,000	294,159,000	172,131,000	425,753,000
Summary
Free Cash Flow	465,383,000	-42,589,000	41,945,000	-613,333,000
Net Change in Cash	690,155,000	153,768,000	-53,672,000	44,241,000